USD 21.97
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| TEVA | -0.2 | 2.2 | -1.1 | 19.3 | 29.6 | 83.2 | 159.7 | 111.5 | -63.3 | 2324.3 |
| S&P 500 | -0.1 | 1.4 | 1.8 | 4.9 | 9.5 | 25.0 | 37.9 | 82.9 | 196.4 | 34333.9 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | TEVA |
| name | Teva Pharmaceutical Industries Limited |
| price | 21.97 |
| changes percentage | -0.1817 |
| change | -0.04 |
| day low | 21.94 |
| day high | 22.11 |
| year high | 22.8 |
| year low | 11.48 |
| market cap | 24926942300 |
| price avg 50 | 19.1602 |
| price avg 200 | 17.38705 |
| exchange | NYSE |
| volume | 332721 |
| avg volume | 9459376 |
| open | 21.94 |
| previous close | 22.01 |
| eps | -0.85 |
| pe | -25.85 |
| earnings announcement | 2025-01-29T12:00:00.000+0000 |
| shares outstanding | 1134590000 |
| timestamp | 2025-01-23 14:37:05 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000818686 | |||
| revenue | 15846000000 | 14925000000 | 6.17 |
| gross profit | 7646000000 | 6973000000 | 9.65 |
| gross profit ratio | 0.48 | 0.47 | 3.28 |
| research and development expenses | 953000000 | 838000000 | 13.72 |
| operating expenses | 7213000000 | 4283000000 | 68.41 |
| interest income | 68000000 | 920000000 | -92.61 |
| interest expense | 1029000000 | 966000000 | 6.52 |
| ebitda | 1570000000 | -874000000 | 279.63 |
| ebitdaratio | 0.1 | 0.28 | -63.98 |
| operating income | 433000000 | 2797000000 | -84.52 |
| operating income ratio | 0.03 | 0.19 | -85.42 |
| net income | -559000000 | -2353000000 | 76.24 |
| net income ratio | -0.04 | -0.16 | 77.62 |
| eps | -0.5 | -2.12 | 76.42 |
Revenue Growth: revenue increased to 15,846 million in 2023 from 14,925 million in 2022 representing a change of 6.17%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 7,646 million in 2023 from 6,973 million in 2022 representing a change of 9.65%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 953 million in 2023 from 838 million in 2022 representing a change of 13.72%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 1,570 million in 2023 from -874 million in 2022 representing a change of 279.63%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to 433 million in 2023 from 2,797 million in 2022 representing a change of -84.52%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -559 million in 2023 from -2,353 million in 2022 representing a change of 76.24%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.5 in 2023 from -0.5 in 2022 representing a change of 76.42%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 7,213 million in 2023 from 4,283 million in 2022 representing a change of 68.41%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000818686 | |||
| revenue | 4332000000 | 4162000000 | 4.08 |
| gross profit | 2148000000 | 2022000000 | 6.23 |
| gross profit ratio | 0.5 | 0.49 | 2.06 |
| research and development expenses | 240000000 | 269000000 | -10.78 |
| operating expenses | 1164000000 | 1208000000 | -3.64 |
| interest income | 0 | 0 | NaN |
| interest expense | 272000000 | 241000000 | 12.86 |
| ebitda | 210000000 | 254000000 | -17.32 |
| ebitdaratio | 0.05 | 0.26 | -81.20 |
| operating income | -51000000 | 814000000 | -106.27 |
| operating income ratio | -0.01 | 0.2 | -106.02 |
| net income | -437000000 | -845000000 | 48.28 |
| net income ratio | -0.1 | -0.2 | 50.31 |
| eps | -0.39 | -0.75 | 48.00 |
Revenue Growth: revenue increased to 4,332 million in 2024Q3 from 4,162 million in 2024Q2 representing a change of 4.08%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 2,148 million in 2024Q3 from 2,022 million in 2024Q2 representing a change of 6.23%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 1,164 million in 2024Q3 from 1,208 million in 2024Q2 representing a change of -3.64%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Earnings per Share (EPS): EPS increased to -0.39 in 2024Q3 from -0.39 in 2024Q2 representing a change of 48.0%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 240 million in 2024Q3 from 269 million in 2024Q2 representing a change of -10.78%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to 210 million in 2024Q3 from 254 million in 2024Q2 representing a change of -17.32%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -51 million in 2024Q3 from 814 million in 2024Q2 representing a change of -106.27%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -437 million in 2024Q3 from -845 million in 2024Q2 representing a change of 48.28%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000818686 | |||
| total assets | 43479000000 | 44006000000 | -1.20 |
| total liabilities | 35353000000 | 35315000000 | 0.11 |
| total equity | 8126000000 | 8691000000 | -6.50 |
| cash and cash equivalents | 3226000000 | 2801000000 | 15.17 |
| short term investments | 0 | 0 | NaN |
| long term investments | 8000000 | 0 | NaN |
| total current assets | 12485000000 | 12051000000 | 3.60 |
| total non current assets | 30994000000 | 31955000000 | -3.01 |
| total current liabilities | 12247000000 | 11469000000 | 6.78 |
| total non current liabilities | 23106000000 | 23846000000 | -3.10 |
| common stock | 57000000 | 57000000 | 0.00 |
| retained earnings | -13534000000 | -12882000000 | -5.06 |
| total debt | 20153000000 | 21561000000 | -6.53 |
Total Assets: Total Assets decreased to 43,479 million in 2023 from 44,006 million in 2022 representing a change of -1.2%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 35,353 million in 2023 from 35,315 million in 2022 representing a change of 0.11%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 8,126 million in 2023 from 8,691 million in 2022 representing a change of -6.5%. This indicates a decrease in shareholders' equity.
Total Current Liabilities: Total Current Liabilities increased to 12,247 million in 2023 from 11,469 million in 2022 representing a change of 6.78%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -13,534 million in 2023 from -12,882 million in 2022 representing a change of -5.06%. This indicates an accumulated losses.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 3,226 million in 2023 from 2,801 million in 2022 representing a change of 15.17%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 12,485 million in 2023 from 12,051 million in 2022 representing a change of 3.6%. This indicates a better liquidity position.
Total Debt: Total Debt decreased to 20,153 million in 2023 from 21,561 million in 2022 representing a change of -6.53%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000818686 | |||
| total assets | 41758000000 | 41338000000 | 1.02 |
| total liabilities | 35374000000 | 34774000000 | 1.73 |
| total equity | 6384000000 | 6563000000 | -2.73 |
| cash and cash equivalents | 3319000000 | 2258000000 | 46.99 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 12314000000 | 11632000000 | 5.86 |
| total non current assets | 29444000000 | 29706000000 | -0.88 |
| total current liabilities | 13797000000 | 13037000000 | 5.83 |
| total non current liabilities | 21577000000 | 21737000000 | -0.74 |
| common stock | 58000000 | 58000000 | 0.00 |
| retained earnings | -14956000000 | -14519000000 | -3.01 |
| total debt | 19275000000 | 18922000000 | 1.87 |
Total Assets: Total Assets increased to 41,758 million in 2024Q3 from 41,338 million in 2024Q2 representing a change of 1.02%. Suggesting a growth in asset holdings.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 3,319 million in 2024Q3 from 2,258 million in 2024Q2 representing a change of 46.99%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 12,314 million in 2024Q3 from 11,632 million in 2024Q2 representing a change of 5.86%. This indicates a better liquidity position.
Total Liabilities: Total Liabilities increased to 35,374 million in 2024Q3 from 34,774 million in 2024Q2 representing a change of 1.73%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 6,384 million in 2024Q3 from 6,563 million in 2024Q2 representing a change of -2.73%. This indicates a decrease in shareholders' equity.
Total Current Liabilities: Total Current Liabilities increased to 13,797 million in 2024Q3 from 13,037 million in 2024Q2 representing a change of 5.83%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -14,956 million in 2024Q3 from -14,519 million in 2024Q2 representing a change of -3.01%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 19,275 million in 2024Q3 from 18,922 million in 2024Q2 representing a change of 1.87%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000818686 | |||
| net change in cash | 393000000 | 636000000 | -38.21 |
| operating cash flow | 1368000000 | 1590000000 | -13.96 |
| free cash flow | 842000000 | 1042000000 | -19.19 |
| capital expenditure | -526000000 | -548000000 | 4.01 |
| depreciation and amortization | 1153000000 | 1308000000 | -11.85 |
| deferred income tax | -317000000 | -1059000000 | 70.07 |
| stock based compensation | 121000000 | 124000000 | -2.42 |
| accounts payables | 1588000000 | 1914000000 | -17.03 |
| inventory | 0 | -163000000 | 100.00 |
| acquisitions net | 68000000 | 61000000 | 11.48 |
| investments in property plant and equipment | -526000000 | -548000000 | 4.01 |
| net cash used for investing activites | 968000000 | 656000000 | 47.56 |
| debt repayment | -1701000000 | -1369000000 | -24.25 |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -1913000000 | -1487000000 | -28.65 |
| cash at end of period | 3227000000 | 2834000000 | 13.87 |
| accounts receivables | 12000000 | 334000000 | -96.41 |
| cash at beginning of period | 2834000000 | 2198000000 | 28.94 |
Net Change in Cash: Net Change in Cash decreased to 393 million in 2023 from 636 million in 2022 representing a change of -38.21%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to 1,368 million in 2023 from 1,590 million in 2022 representing a change of -13.96%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to 842 million in 2023 from 1,042 million in 2022 representing a change of -19.19%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -526 million in 2023 from -548 million in 2022 representing a change of 4.01%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to -317 million in 2023 from -1,059 million in 2022 representing a change of 70.07%. This indicates that the company's tax liability for future periods has increased.
Stock-Based Compensation: Stock-Based Compensation decreased to 121 million in 2023 from 124 million in 2022 representing a change of -2.42%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 1,588 million in 2023 from 1,914 million in 2022 representing a change of -17.03%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to 12 million in 2023 from 334 million in 2022 representing a change of -96.41%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000818686 | |||
| operating cash flow | 693000000 | 420000000 | 65.00 |
| free cash flow | 545000000 | 323000000 | 68.73 |
| capital expenditure | -148000000 | -97000000 | -52.58 |
| depreciation and amortization | 259000000 | 259000000 | 0.00 |
| deferred income tax | -53000000 | -424000000 | 87.50 |
| stock based compensation | 29000000 | 32000000 | -9.38 |
| accounts receivables | 339000000 | 317000000 | 6.94 |
| accounts payables | 0 | 0 | NaN |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 1000000 | -100.00 |
| investments in property plant and equipment | -148000000 | -97000000 | -52.58 |
| net cash used for investing activites | 268000000 | -139000000 | 292.81 |
| debt repayment | 0 | -956000000 | 100.00 |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 0 | -966000000 | 100.00 |
| net change in cash | 1061000000 | -733000000 | 244.75 |
| cash at end of period | 3319000000 | 2258000000 | 46.99 |
| cash at beginning of period | 2258000000 | 2991000000 | -24.51 |
Net Change in Cash: Net Change in Cash increased to 1,061 million in 2024Q3 from -733 million in 2024Q2 representing a change of 244.75%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 693 million in 2024Q3 from 420 million in 2024Q2 representing a change of 65.0%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 545 million in 2024Q3 from 323 million in 2024Q2 representing a change of 68.73%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -148 million in 2024Q3 from -97 million in 2024Q2 representing a change of -52.58%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 29 million in 2024Q3 from 32 million in 2024Q2 representing a change of -9.38%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Deferred Income Tax: Deferred Income Tax increased to -53 million in 2024Q3 from -424 million in 2024Q2 representing a change of 87.5%. This indicates that the company's tax liability for future periods has increased.
Accounts Receivables: Accounts Receivables increased to 339 in 2024Q3 from 317 million in 2024Q2 representing a change of 6.94%. This suggests that the company is less capable of collecting payments from its customers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 14.17 | 13.45 | 5.41 |
| net income per share | -0.5 | -2.12 | 76.41 |
| operating cash flow per share | 1.22 | 1.43 | -14.58 |
| free cash flow per share | 0.75 | 0.94 | -19.77 |
| cash per share | 2.89 | 2.52 | 14.35 |
| book value per share | 7.27 | 7.83 | -7.17 |
| tangible book value per share | -12.91 | -13.7 | 5.77 |
| shareholders equity per share | 6.71 | 7.11 | -5.63 |
| interest debt per share | 18.95 | 20.29 | -6.64 |
| market cap | 11827040823 | 10027478373 | 17.95 |
| enterprise value | 28754040823 | 28787478373 | -0.12 |
| pe ratio | -21.16 | -4.26 | -396.47 |
| price to sales ratio | 0.75 | 0.67 | 11.09 |
| pocfratio | 8.65 | 6.31 | 37.09 |
| pfcf ratio | 14.05 | 9.62 | 45.96 |
| pb ratio | 1.58 | 1.27 | 24.09 |
| ptb ratio | 1.58 | 1.27 | 24.09 |
| ev to sales | 1.81 | 1.93 | -5.92 |
| enterprise value over ebitda | 18.46 | -31.12 | 159.30 |
| ev to operating cash flow | 21.02 | 18.11 | 16.09 |
| ev to free cash flow | 34.15 | 27.63 | 23.61 |
| earnings yield | -0.05 | -0.23 | 79.86 |
| free cash flow yield | 0.07 | 0.1 | -31.49 |
| debt to equity | 2.68 | 2.73 | -1.66 |
| debt to assets | 0.46 | 0.49 | -5.40 |
| net debt to ebitda | 10.86 | -20.28 | 153.57 |
| current ratio | 1.02 | 1.05 | -2.98 |
| interest coverage | 0.42 | -2.17 | 119.37 |
| income quality | -2.45 | -0.66 | -270.32 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.07 | 0.08 | -7.25 |
| research and ddevelopement to revenue | 0.07 | 0.06 | 17.23 |
| intangibles to total assets | 0.52 | 0.54 | -4.46 |
| capex to operating cash flow | 0.38 | 0.34 | 11.56 |
| capex to revenue | 0.03 | 0.04 | -9.59 |
| capex to depreciation | 0.46 | 0.42 | 8.89 |
| stock based compensation to revenue | 0.01 | 0.01 | -8.09 |
| graham number | 8.69 | 18.42 | -52.82 |
| roic | 0.01 | -0.05 | 127.20 |
| return on tangible assets | -0.03 | -0.12 | 77.17 |
| graham net net | -24.65 | -25.07 | 1.66 |
| working capital | 238000000 | 582000000 | -59.11 |
| tangible asset value | -14438000000 | -15212000000 | 5.09 |
| net current asset value | -22868000000 | -23264000000 | 1.70 |
| invested capital | 28949000000 | 30643000000 | -5.53 |
| average receivables | 3552000000 | 4112500000 | -13.63 |
| average payables | 2244500000 | 1786500000 | 25.64 |
| average inventory | 3927000000 | 3825500000 | 2.65 |
| days sales outstanding | 78.5 | 90.39 | -13.15 |
| days payables outstanding | 115.82 | 86.61 | 33.72 |
| days of inventory on hand | 178.98 | 175.94 | 1.73 |
| receivables turnover | 4.65 | 4.04 | 15.14 |
| payables turnover | 3.15 | 4.21 | -25.22 |
| inventory turnover | 2.04 | 2.07 | -1.70 |
| roe | -0.07 | -0.3 | 75.01 |
| capex per share | 0.47 | 0.49 | -4.70 |
ROE: Return on Equity (ROE) increased to -0.07 on 2023-12-31 from -0.30 on 2022-12-31, representing a change of 75.01%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -21.16 on 2023-12-31 from -4.26 on 2022-12-31, representing a change of -396.47%. Indicating a decrease in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 2.68 on 2023-12-31 from 2.73 on 2022-12-31, representing a change of -1.66%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. However, a ratio of 2.0 or higher is usually considered risky.
Current Ratio: Current Ratio decreased to 1.02 on 2023-12-31 from 1.05 on 2022-12-31, representing a change of -2.98%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| TEVA | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 3.82 | 3.69 | 3.55 |
| net income per share | -0.39 | -0.75 | 48.57 |
| operating cash flow per share | 0.61 | 0.09 | 569.85 |
| free cash flow per share | 0.48 | 0.01 | 8943.25 |
| cash per share | 2.93 | 2.0 | 46.34 |
| book value per share | 5.63 | 5.82 | -3.16 |
| tangible book value per share | -12.8 | -13.1 | 2.33 |
| shareholders equity per share | 5.35 | 5.64 | -5.04 |
| interest debt per share | 17.25 | 16.99 | 1.55 |
| market cap | 20127058628.6 | 17914162010.4 | 12.35 |
| enterprise value | 36083058628.6 | 34578162010.4 | 4.35 |
| pe ratio | -11.51 | -5.29 | -117.51 |
| price to sales ratio | 4.65 | 4.3 | 8.02 |
| pocfratio | 29.04 | 173.92 | -83.30 |
| pfcf ratio | 36.93 | 2985.69 | -98.76 |
| pb ratio | 3.32 | 2.82 | 17.80 |
| ptb ratio | 3.32 | 2.82 | 17.80 |
| ev to sales | 8.33 | 8.3 | 0.33 |
| enterprise value over ebitda | 174.31 | 136.13 | 28.05 |
| ev to operating cash flow | 52.07 | 335.71 | -84.49 |
| ev to free cash flow | 66.21 | 5763.03 | -98.85 |
| earnings yield | -0.02 | -0.05 | 54.02 |
| free cash flow yield | 0.03 | 0.0 | 7984.65 |
| debt to equity | 3.18 | 2.98 | 6.80 |
| debt to assets | 0.46 | 0.46 | 0.84 |
| net debt to ebitda | 77.08 | 65.61 | 17.49 |
| current ratio | 0.89 | 0.89 | 0.03 |
| interest coverage | -0.19 | -0.02 | -803.75 |
| income quality | -1.78 | -0.12 | -1407.80 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.07 | 0.07 | 1.24 |
| research and ddevelopement to revenue | 0.06 | 0.07 | -17.30 |
| intangibles to total assets | 0.5 | 0.52 | -3.14 |
| capex to operating cash flow | 0.21 | 0.94 | -77.32 |
| capex to revenue | 0.03 | 0.02 | 46.69 |
| capex to depreciation | 0.57 | 0.37 | 52.58 |
| stock based compensation to revenue | 0.01 | 0.01 | -12.87 |
| graham number | 6.82 | 9.75 | -30.12 |
| roic | -0.0 | -0.0 | -244.74 |
| return on tangible assets | -0.02 | -0.04 | 50.52 |
| graham net net | -24.25 | -24.58 | 1.34 |
| working capital | -1483000000 | -1405000000 | -5.55 |
| tangible asset value | -14497000000 | -14778000000 | 1.90 |
| net current asset value | -23060000000 | -23143000000 | 0.36 |
| invested capital | 25434000000 | 25867000000 | -1.67 |
| average receivables | 3614000000 | 3611000000 | 0.08 |
| average payables | 2368500000 | 2402500000 | -1.42 |
| average inventory | 3943000000 | 3938000000 | 0.13 |
| days sales outstanding | 71.94 | 81.4 | -11.62 |
| days payables outstanding | 97.75 | 99.5 | -1.76 |
| days of inventory on hand | 163.22 | 165.15 | -1.17 |
| receivables turnover | 1.25 | 1.11 | 13.14 |
| payables turnover | 0.92 | 0.9 | 1.79 |
| inventory turnover | 0.55 | 0.54 | 1.18 |
| roe | -0.07 | -0.13 | 45.84 |
| capex per share | 0.13 | 0.09 | 51.90 |
ROE: Return on Equity (ROE) increased to -0.07 on 2024-09-30 Q3 from -0.13 on 2024-06-30 Q2, representing a change of 45.84%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -11.51 on 2024-09-30 Q3 from -5.29 on 2024-06-30 Q2, representing a change of -117.51%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 0.89 on 2024-09-30 Q3 from 0.89 on 2024-06-30 Q2, representing a change of 0.03%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 3.18 on 2024-09-30 Q3 from 2.98 on 2024-06-30 Q2, representing a change of 6.80%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. A ratio of 2.0 or higher is usually considered risky.
Negative Sentiment: Discounted Cash Flow value is -4.17 which is lower than current price 21.97, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-19 16:54:45
This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to exceed $190 billion by 2028. Every year, regulatory agencies approve dozens of biosimilars and brand-name drugs, so Seeking Alpha readers should be careful when making decisions.
Sentiment: Negative
Publish Date: 2025-01-13 14:00:01
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 11:15 AM ET Company Participants Richard Francis - President and CEO Eric Hughes - Head of R&D and Chief Medical Officer Conference Call Participants Chris Schott - J.P.
Sentiment: Neutral
Publish Date: 2025-01-13 13:03:53
Pharmaceutical companies brace for the upcoming Trump administration. Teva Pharmaceuticals (TEVA) CEO Richard Francis joins Seana Smith and Madison Mills on Catalysts to discuss what both the pharmaceutical company and industry at large are expecting from Trump's return to the White House.
Sentiment: Positive
Publish Date: 2025-01-13 10:35:48
Teva Pharmaceuticals CEO Richard Francis reflects on company performance in 2024, drug pricing, getting more drugs to market, supply shortages of the drug Adderall, and selling GLP-1 drugs. He speaks to "Bloomberg Open Interest" from the JPMorgan Healthcare Conference.
Sentiment: Neutral
Publish Date: 2025-01-13 01:00:00
TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) today announced that it has entered into a strategic collaboration with Klinge Biopharma GmbH (Klinge) and Formycon AG (FSE: FYB) for the semi-exclusive commercialization of FYB203, Formycon's biosimilar candidate to Eylea® (aflibercept) in Europe, excluding Italy, and in Israel.
Sentiment: Positive
Publish Date: 2025-01-10 08:30:00
INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced today that the companies have entered into a license, development and commercialization agreement for EPYSQLI® (eculizumab-aagh), Samsung Bioepis' biosimilar to Soliris® i (eculizumab-aagh) in the United States (U.S.).
Sentiment: Positive
Publish Date: 2024-12-27 15:21:29
On December 17, Teva Pharmaceutical Industries Limited reported that duvakitug had shown stunning results in a phase 2b study for the treatment of Crohn's disease and ulcerative colitis. However, a month and a half before this news, the Israeli pharmaceutical company pleased investors by once again beating analysts' expectations by a wide margin. So, Uzedy's sales amounted to $35 million in the third quarter of 2024, increasing more than 16 times year-on-year.
Sentiment: Positive
Publish Date: 2024-12-24 04:51:00
Over the last two years, there hasn't been a hotter trend on Wall Street than the rise of artificial intelligence (AI). The ability for AI-powered software and systems to become more proficient at their existing tasks, as well as evolve to learn new jobs over time without human intervention, gives this technology a virtually limitless ceiling and broad-based utility in most industries.
Sentiment: Neutral
Publish Date: 2024-12-23 16:30:00
TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time).
Sentiment: Positive
Publish Date: 2024-12-20 16:30:00
TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2024 financial results, as well as on its financial guidance for 2025, on Wednesday, January 29, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Sentiment: Positive
Publish Date: 2024-12-18 14:29:55
Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD).
Sentiment: Positive
Publish Date: 2024-12-18 09:25:35
Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.
Sentiment: Positive
Publish Date: 2024-12-18 07:41:18
Teva Pharmaceutical Industries (TEVA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Sentiment: Neutral
Publish Date: 2024-12-18 04:32:30
Teva Pharmaceuticals (NASDAQ: TEVA) and its partner Sanofi (NASDAQ: SNY) have announced groundbreaking results from clinical trials of their drug, duvakitug, for ulcerative colitis and Crohn's disease, two of the most prevalent forms of inflammatory bowel disease (IBD). The announcement, which sent Teva's stock soaring by 26.4% to $20.88 and Sanofi's up 6.7% to $48.
Sentiment: Neutral
Publish Date: 2024-12-17 16:50:01
Teva Pharmaceutical (TEVA) closed at its highest stock price of the year after it and Sanofi (SNY) say their IBD treatment had higher remission in trial. George Tsilis looks at how the development can be the first step in a turnaround for the company.
Sentiment: Positive
Publish Date: 2024-12-17 14:25:47
U.S.-traded shares of Teva Pharmaceuticals (TEVA) and Sanofi (SNY) took off Tuesday after the two drugmakers reported positive results from a study of their treatment for ulcerative colitis (UC) and Crohn's disease.
Sentiment: Positive
Publish Date: 2024-12-17 14:18:32
TD Cowen analyst Tyler Van Buren recommends buying shares of Spyre Therapeutics (SYRE) following the "impressive results" from Teva (TEVA) and Sanofi (SNY) in inflammatory bowel diseases. Similar to its bigger rivals, Spyre has an anti-TL1A monoclonal antibody in its product pipeline, known as SPY002, the analyst tells investors in a research note. TD believes Spyre has the "superior TL1A program" and its combination treatments under development "will further elevate outcomes." Teva and Sanofi's results "further validate TL1A inhibition as a highly promising mechanism" for both ulcerative colitis and Crohn's disease, contends the firm. Spyre Therapeutics +0.105 (+0.43%) Teva +4.32 (+26.18%) Sanofi +3.38 (+7.37%)
Sentiment: Positive
Publish Date: 2024-12-17 14:03:04
BTIG analyst Julian Harrison notes that Teva's (TEVA) enterprise value has increased by more than $4B today after Phase 2b UC/CD data of a TL1A asset that "they only own 50% rights to" plus $1B in development and launch milestones. The firm's "main takeaways" for Spyre Therapeutics (SYRE) from today's update from Teva are that strong market demand for anti-TL1A assets has "not faded at all" and the upside potential for SPY002 "looks even further reinforced," as BTIG expects the TL1A constructs that Spyre is developing to "likely leapfrog the broader class both on efficacy and dosing." The firm, which keeps a Buy rating and $70 price target on Spyre shares, views the relative weakness following the duvakitug data as a buying opportunity, the analyst tells investors. Spyre Therapeutics -0.005 (-0.02%) Teva +4.385 (+26.58%)
Sentiment: Positive
Publish Date: 2024-12-17 13:23:59
BofA raised the firm's price target on Teva to $25 from $23 and keeps a Buy rating on the shares. The price target increase reflects the strong Phase 2 update for duvakitug as a treatment for inflammatory bowel disorders, the analyst tells investors in a research note. The firm now forecasts nominal peak sales of roughly $2B, with Teva booking half the profits, based on the strength of the data and the emerging product profile.
Sentiment: Positive
Publish Date: 2024-12-17 11:51:00
Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
